$4.65
Agenus is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.87 – a decrease of 11.13% over the previous week. Agenus employs 389 staff and has a trailing 12-month revenue of around $159.6 million.
Our top picks for where to buy Agenus stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
How to buy Agenus stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AGEN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Agenus stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Agenus stock price (NASDAQ: AGEN)
Use our graph to track the performance of AGEN stocks over time.Agenus shares at a glance
Latest market close | $4.87 |
---|---|
52-week range | $4.41 - $23.20 |
50-day moving average | $5.53 |
200-day moving average | $11.18 |
Wall St. target price | $9.75 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-11.50 |
Is it a good time to buy Agenus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Agenus price performance over time
Historical closes compared with the close of $4.87 from 2024-10-04
1 week (2024-10-01) | -4.51% |
---|---|
1 month (2024-09-06) | -1.62% |
3 months (2024-07-08) | -68.70% |
6 months (2024-04-08) | 946.19% |
1 year (2023-10-06) | 359.43% |
---|---|
2 years (2022-10-07) | 81.72% |
3 years (2021-10-08) | 5.72 |
5 years (2019-10-08) | 84.47% |
Agenus financials
Revenue TTM | $159.6 million |
---|---|
Gross profit TTM | $82.6 million |
Return on assets TTM | -21.04% |
Return on equity TTM | -1278.83% |
Profit margin | -139.99% |
Book value | $-11.42 |
Market Capitalization | $118.2 million |
TTM: trailing 12 months
Agenus share dividends
We're not expecting Agenus to pay a dividend over the next 12 months.
Have Agenus's shares ever split?
Agenus's shares were split on a 1:20 basis on 11 April 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.
Agenus share price volatility
Over the last 12 months, Agenus's shares have ranged in value from as little as $4.41 up to $23.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.357. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agenus overview
Agenus Inc. , a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks.
Frequently asked questions
nullWhat percentage of Agenus is owned by insiders or institutions?
Currently 1.276% of Agenus shares are held by insiders and 41.649% by institutions. How many people work for Agenus?
Latest data suggests 389 work at Agenus. When does the fiscal year end for Agenus?
Agenus's fiscal year ends in December. Where is Agenus based?
Agenus's address is: 3 Forbes Road, Lexington, MA, United States, 02421-7305 What is Agenus's ISIN number?
Agenus's international securities identification number is: US00847G7051 What is Agenus's CUSIP number?
Agenus's Committee on Uniform Securities Identification Procedures number is: 037032109
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question